AU2018345601B2 - Methods and compositions for inhibiting ADAM10 biological activities - Google Patents

Methods and compositions for inhibiting ADAM10 biological activities Download PDF

Info

Publication number
AU2018345601B2
AU2018345601B2 AU2018345601A AU2018345601A AU2018345601B2 AU 2018345601 B2 AU2018345601 B2 AU 2018345601B2 AU 2018345601 A AU2018345601 A AU 2018345601A AU 2018345601 A AU2018345601 A AU 2018345601A AU 2018345601 B2 AU2018345601 B2 AU 2018345601B2
Authority
AU
Australia
Prior art keywords
adam10
inhibiting
compositions
methods
biological activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018345601A
Other languages
English (en)
Other versions
AU2018345601A1 (en
Inventor
Marcia L. Moss
Chris Prince
Robert Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verra Therapeutics LLC
Original Assignee
Verra Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics LLC filed Critical Verra Therapeutics LLC
Publication of AU2018345601A1 publication Critical patent/AU2018345601A1/en
Assigned to Verra Therapeutics LLC reassignment Verra Therapeutics LLC Amend patent request/document other than specification (104) Assignors: VERRA THERAPEUTICS
Application granted granted Critical
Publication of AU2018345601B2 publication Critical patent/AU2018345601B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24081—ADAM10 endopeptidase (3.4.24.81)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2018345601A 2017-10-02 2018-10-02 Methods and compositions for inhibiting ADAM10 biological activities Active AU2018345601B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762566580P 2017-10-02 2017-10-02
US62/566,580 2017-10-02
US201762589842P 2017-11-22 2017-11-22
US62/589,842 2017-11-22
PCT/US2018/053938 WO2019070685A1 (en) 2017-10-02 2018-10-02 METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10

Publications (2)

Publication Number Publication Date
AU2018345601A1 AU2018345601A1 (en) 2020-05-21
AU2018345601B2 true AU2018345601B2 (en) 2025-05-15

Family

ID=65995419

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018345601A Active AU2018345601B2 (en) 2017-10-02 2018-10-02 Methods and compositions for inhibiting ADAM10 biological activities

Country Status (8)

Country Link
US (3) US20190345473A1 (enExample)
EP (1) EP3691671A4 (enExample)
JP (2) JP7448219B2 (enExample)
AU (1) AU2018345601B2 (enExample)
CA (1) CA3077694A1 (enExample)
IL (1) IL273725A (enExample)
MX (1) MX2020004218A (enExample)
WO (1) WO2019070685A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094136A1 (en) 2018-01-31 2019-08-08 Verra Therapeutics LLC Methods and compositions for inhibiting adam9 biological activities
US20220213169A1 (en) * 2019-05-09 2022-07-07 Verra Therapeutics, Llc Methods and compositions for inhibiting adam8 biological activities
JP2025507975A (ja) * 2022-03-08 2025-03-21 ノバ サウスイースタン ユニバーシティー ディスインテグリンおよびメタロプロテアーゼ１０（ａｄａｍ１０）の酵素・基質選択的エキソサイト阻害剤を用いた関節リウマチ（ｒａ）の処置方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096820A1 (en) * 2006-08-28 2008-04-24 Biozyme, Inc. Prodomain modulators of ADAM 10

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024089A2 (en) 2002-09-11 2004-03-25 Sloan-Kettering Institute For Cancer Research Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
AU2004240630B2 (en) * 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
CN101142236B (zh) 2005-02-02 2013-03-20 雷文生物技术公司 Adam-9调节剂
CA2604883A1 (en) 2005-04-07 2006-10-19 Albert Lai Adam10 in cancer diagnosis, detection and treatment
US20090285840A1 (en) 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US8079782B1 (en) 2008-05-16 2011-12-20 Hilfiker William K Semi-extensible steel soil reinforcements for mechanically stabilized embankments
EP2637679A4 (en) * 2010-11-09 2015-09-23 Univ Chicago ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASES AND THERAPEUTICS
WO2012088105A2 (en) * 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer
US10023653B2 (en) 2014-02-04 2018-07-17 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096820A1 (en) * 2006-08-28 2008-04-24 Biozyme, Inc. Prodomain modulators of ADAM 10

Also Published As

Publication number Publication date
IL273725A (en) 2020-05-31
US20230203468A1 (en) 2023-06-29
JP2024012470A (ja) 2024-01-30
US20190345473A1 (en) 2019-11-14
WO2019070685A1 (en) 2019-04-11
JP2021500321A (ja) 2021-01-07
CA3077694A1 (en) 2019-04-11
AU2018345601A1 (en) 2020-05-21
EP3691671A1 (en) 2020-08-12
JP7448219B2 (ja) 2024-03-12
MX2020004218A (es) 2020-11-11
US12297469B2 (en) 2025-05-13
EP3691671A4 (en) 2022-01-19
US20250207119A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
IL271193A (en) Preparations and methods for internalizing enzymes
EP3664816A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
EP3568385A4 (en) PROCEDURES AND COMPOSITIONS FOR IMPROVING PLANT PROPERTIES
EP3665156A4 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES
EP3405577B8 (en) Compositions and methods for inhibiting factor d
EP3585433A4 (en) THERAPEUTIC COMPOSITIONS AND ASSOCIATED METHODS FOR PHOTOIMMUNOTHERAPY
EP3313410A4 (en) Compositions and methods for inhibiting arginase activity
EP3442543A4 (en) COMPOSITIONS AND METHODS FOR NEUROGENESIS
EP3268018A4 (en) Bacterial compositions and methods of use thereof
EP3288387A4 (en) Microbial compositions and methods for bioprotection
EP3122346A4 (en) Trka kinase inhibitors, compositions and methods thereof
EP3122344A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3253389A4 (en) Apilimod compositions and methods for using same
TWI799417B (zh) 生物製藥組成物及相關方法
EP3215176A4 (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules
EP3286179A4 (en) Compositions and methods for inhibiting kinases
EP3256592A4 (en) Compositions and methods for modulating rna
AU2018345601B2 (en) Methods and compositions for inhibiting ADAM10 biological activities
EP3113774A4 (en) Compositions of grapiprant and methods for using the same
EP3356357A4 (en) COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE
EP3596082A4 (en) CDPK1 INHIBITORS, ASSOCIATED COMPOSITIONS AND PROCESSES
EP3612230A4 (en) PALBOCICLIB COMPOSITIONS AND RELATED METHODS
EP3325448A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE GROWTH OF MULTIRESISTENT MICROBES
EP3204120A4 (en) Methods and compositions for increasing the potency of antifungal agents
HK40115827A (zh) 用於抑制ldha表达的方法和组合物

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: VERRA THERAPEUTICS LLC

Free format text: FORMER NAME(S): VERRA THERAPEUTICS

FGA Letters patent sealed or granted (standard patent)